[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 4, 2019

A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management

Author Affiliations
  • 1Duke University Medical Center, Durham, North Carolina
  • 2Associate Editor, JAMA
  • 3Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 4Senior Editor, JAMA
JAMA. 2019;321(8):749-750. doi:10.1001/jama.2019.0045

Elevated serum cholesterol is one of the world’s most common and modifiable risk factors for cardiovascular disease (CVD). In the 5 years since the release of the 2013 American Heart Association/American College of Cardiology (AHA/ACC) guideline for lipid management,1 there have been multiple advances in lipid biology, epidemiology, and therapeutic clinical trials. This wealth of new evidence led the AHA/ACC to release a major revision of the lipid practice recommendations in 2018.2 Overall, the new guidelines are more evidence based and personalized than in the past but also more complex. The full content of the new lipid guidelines is contained in a well-referenced 65-page document and summarized in 10 succinct top messages highlighted in this issue of JAMA.3